Maxygen and Roche Holding entered into licensing agreement for worldwide commercialization rights to Maxygen’s lead interferon product candidates for the treatment of hepatitis B and hepatitis C viral infections. The deal could be worth up to US$230 M to Maxygen if specific milestones and sales targets are met.